BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook
Portfolio Pulse from
Bristol-Myers Squibb (BMY) reported better-than-expected earnings and sales for Q4 2024. Despite this, the company's shares fell due to a disappointing 2025 outlook.
February 06, 2025 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bristol-Myers Squibb reported strong Q4 2024 earnings and sales, surpassing estimates. However, the stock price declined due to a lower-than-expected 2025 outlook.
The positive earnings and sales results for Q4 2024 were overshadowed by the company's guidance for 2025, which did not meet market expectations. This has led to a negative reaction in the stock price as investors are concerned about future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100